These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25914397)

  • 21. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
    Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
    Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J;
    Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Outcomes of Different Two-Stent Techniques With Second-Generation Drug-Eluting Stents for Unprotected Left Main Bifurcation Disease: Insights From the FAILS-2 Study.
    Pavani M; Conrotto F; Cerrato E; D'Ascenzo F; Kawamoto H; Núñez-Gil IJ; Pennone M; Garbo R; Tomassini F; Colombo F; Scacciatella P; Varbella F; Chieffo A; Colombo A; Escaned J
    J Invasive Cardiol; 2018 Aug; 30(8):276-281. PubMed ID: 30068784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
    Silber S; Windecker S; Vranckx P; Serruys PW;
    Lancet; 2011 Apr; 377(9773):1241-7. PubMed ID: 21459430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent.
    Lee M; Hiremath S; Zambahari R; Leon M; Mauri L; Yeung A;
    Am J Cardiol; 2013 Nov; 112(9):1335-41. PubMed ID: 23953695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review.
    Yang JX; Yeh RW
    Future Cardiol; 2018 May; 14(3):251-267. PubMed ID: 29448810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system.
    Triantafyllis AS; Bennett J; Pagourelias E; McCutcheon K; Adriaenssens T; Sinnaeve PR; Desmet W; Dubois C
    Cardiol J; 2018; 25(4):470-478. PubMed ID: 29240962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial.
    Diletti R; Garcia-Garcia HM; Bourantas CV; van Geuns RJ; Van Mieghem NM; Vranckx P; Zhang YJ; Farooq V; Iqbal J; Wykrzykowska JJ; de Vries T; Swart M; Teunissen Y; Negoita M; van Leeuwen F; Silber S; Windecker S; Serruys PW;
    Heart; 2013 Sep; 99(17):1267-74. PubMed ID: 23800571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Angiographic Outcomes Comparison of Patients With Left Main Vs Non-Left Main Bifurcation Lesions Treated With Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents.
    Vergara R; Valenti R; Migliorini A; Ciabatti M; Grazia De Gregorio M; Taborchi G; Morini S; Rondine R; Martone R; Antoniucci D
    J Invasive Cardiol; 2018 Dec; 30(12):443-446. PubMed ID: 30504512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
    JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
    Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
    Chen SL; Sheiban I; Xu B; Jepson N; Paiboon C; Zhang JJ; Ye F; Sansoto T; Kwan TW; Lee M; Han YL; Lv SZ; Wen SY; Zhang Q; Wang HC; Jiang TM; Wang Y; Chen LL; Tian NL; Cao F; Qiu CG; Zhang YJ; Leon MB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1266-76. PubMed ID: 25326748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access: the DELIVER study.
    Polad J; Wöhrle J; Singh B; Chag M; Rha SW; Malik FT; van Eck M; Rottbauer W;
    Cardiovasc Revasc Med; 2014; 15(5):289-94. PubMed ID: 25178669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.